We are Sorry, This Page doesn't Exist
Veru"s stock soars again on heavy volume after positive results of breast cancer treatment
Shares of Veru Inc. soared 51.4% toward a seven-year high on massive volume, after the biopharmaceutical company announced positive results from a Phase 2 study of its treatment.....»»
Seattle Genetics Rallies To Record High On Positive Results From Midstage Breast Cancer Study
Shares of the large-cap biopharma Seattle Genetics, Inc. (NASDAQ: SGEN) were advancing strongly Monday following a clinical trial readout from the company. read more.....»»
Why Celldex Therapeutics Is Getting Crushed
Celldex Therapeutics shares were absolutely crushed on Monday morning after the firm announced results to its midstage breast cancer study......»»
Positive Late-Stage Trial Not Enough to Move the Needle for Pfizer
Pfizer shares slipped slightly on Monday morning after the firm announced results from its late-stage trial of breast cancer. Ultimately the results were positive but not exactly what the study was........»»
Myriad Genetics to share results for breast cancer risk assessment study at ASCO
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally
read more.....»»
Why Immunomedics Stock More Than Doubled
Immunomedics shares soared on Monday after the announcements that a late-stage breast cancer study was halted early and a new chief executive officer was named......»»
Applied Genetic Slumps Despite Encouraging Data For Gene Therapy To Treat Rare Inherited Visual Disorder
Shares of Applied Genetic Technologies Corp (NASDAQ: AGTC) are tumbling Thursday despite the company reporting encouraging results from an Phase 1/2 study. 0 read more.....»»
Could This Breast Cancer Study Be the Next Big Thing?
Immunomedics shares made a handy gain on Thursday after the company announced that the FDA has accepted its Biologics License Application for its breast cancer treatment......»»
Puma Biotechnology presents Phase II results of neratinib in breast cancer
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Why This Is a Huge Win Against Prostate Cancer
Myovant Sciences shares more than doubled on Tuesday after the firm announced results from its Phase 3 Hero study of relugolix for prostate cancer......»»
Why Investors Are Pumping the Brakes on NextCure’s Cancer Treatment
NextCure updated clinical results from its early stage cancer study at the Society for Immunotherapy of Cancer annual meeting. As a result, NextCure shares were crushed on Monday......»»
AstraZeneca"s Triple Combo Lung Cancer Therapy Aces Late-Stage Trial
AstraZeneca plc (NYSE: AZN) shares were advancing Monday following a clinical readout from the company. What Happened The U.K.-based pharma giant said its Phase 3 POSEIDON trial produced positive results. read more.....»»
Big Step Forward in HER2-Positive Breast Cancer Trial
Seattle Genetics shares jumped on Monday after the firm announced positive results from its midstage breast cancer trial......»»
Why Parkinson’s Patients Should Be Optimistic About Acadia’s Study
Acadia shares made a handy gain on Monday after the firm announced positive results from an eight-week Phase 2 study evaluating pimavanserin as a therapy for Parkinson’s disease patients with........»»
Surprising Reaction to Lung Cancer Study Results
Eli Lilly shares dipped on Monday after the firm announced results from its midstage clinical trial for the treatment of lung cancer......»»
What This Recent FDA Move Could Mean for Breast Cancer Patients With Brain Metastases
Puma Biotechnology shares jumped early Wednesday after FDA news about Puma’s breast cancer treatment. However, Puma shares quickly fell off from this FDA sugar high......»»
Puma"s Breast Cancer Drug Accorded Orphan Drug Designation For Brain Metastases
Puma Biotechnology Inc (NASDAQ: PBYI) shares advanced in premarket trading Wednesday on the back of an announcement concerning its breast cancer drug Nerlynx before falling after the mark read more.....»»
Why Array BioPharma Shares Fell Thursday
Pharmaceutical company Array BioPharma Inc. (NASDAQ: ARRY) shares dipped more than 3 percent Thursday following comments from a sell-side analyst that investors may have to wait longer for results from Array's BeaconCRC colon cancer study. read more.....»»
Solid Breast Cancer Results From MacroGenics Ahead of ASCO
MacroGenics announced additional details of the results from the Phase 3 Sophia study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with........»»